• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka

Drug Transport(ers) and the Diseased Brain

Proceedings of the Esteve Foundation Symposium 11, held between 6 and 9 October 2004, (S'Agaró, Girona), Spain, ICS 1277

9780444517166
630,00 zł
567,00 zł Zniżka 63,00 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 567,00 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
There are many potent drugs available for many diseases of the brain (e.g. Alzheimers Disease, Parkinsons Disease, Multiple Sclerosis, Stroke, Brain tumors) The effectiviness however is not optimal since barriers in the brain prevent the drugs from reaching the brain in sufficient therapeutic concentrations (e.g. the blood-brain barrier and the blood-cerebrospinal fluid barrier).
Drug Transport(ers) and the Diseased Brain contains the papers of a timely symposium held in Spain between 6 and 9 October 2004, which sets out not only the point of view of the academic researcher and the clinician, but also from the pharmaceutical industrial on how to overcome these barriers and how to treat brain diseases effectively.
Szczegóły produktu
Mosby
47791
9780444517166
9780444517166

Opis

Rok wydania
2005
Numer wydania
1
Oprawa
twarda
Liczba stron
284
Wymiary (mm)
165 x 240
Waga (g)
612
  • About the Esteve Foundation.
    Disclaimer.
    Group photo.
    Introduction and Acknowledgements.
    List of participants.
    Preface.

    The conditions for considering drug transport/targeting to the brain.
    Physiology of the blood-brain barrier and its consequences for drug transport to the
    brain (N.J. Abbott).
    The blood-brain barrier and treatment of lysosomal storage diseases (J.M. Aerts et al.).
    The priorities/needs of the pharmaceutical industry in drug delivery to the brain (M. Lemaire, S. Desrayaud).
    Influx transporters and drug targeting.
    Drug and gene targeting to the brain via blood-brain barrier receptor-mediated
    transport systems (W.M. Pardridge).
    Carrier-mediated transport to enhance drug delivery to brain (Q.R. Smith).
    Influx transporters and drug targeting: Application of peptide and cation transporters (A. Tsuji).
    Application of nanoparticles for the delivery of drugs to the brain (J. Kreuter).
    Application, efficiency and cargo-dependence of transport peptides (J.P.M. Langedijk, T. Olijhoek, R.H. Meloen).
    Efflux transporters at BBB.
    Efflux transport systems at the blood-brain barrier and blood CSF barrier (H. Kusuhara, Y. Sugiyama).
    Experimental models to evaluate the role of P-glycoprotein in the blood-brain tumor barrier (O. van Tellingen, E.M. Kemper, T. Buckle).
    Overcoming MDR at the blood-brain barrier (G. Fricker).
    Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by RNA interference (H. Lage).
    The multidrug resistance protein BMDP/ABCG2: A new and highly relevant efflux pump at the blood-brain barrier (A. Drees et al.).
    Additional approaches for drug delivery/targeting to the BBB/brain.
    Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier (R. Gabathuler et al.).
    Diphtheria toxin receptor-targeted brain drug delivery (P.J. Gaillard, A. Brink, A.G. de Boer).
    The use of Pep: Trans vectors for the delivery of drugs into the central nervous
    system (J.-M. Scherrmann, J. Temsamani).
    Single domain antibodies as blood-brain barrier delivery vectors (A. Abulrob et al.).
    The BBB as a drug target from the clinical point of view.
    The blood-brain barrier in trauma, stroke and edema (J. Verlooy, J. Van Reempts).
    The blood-brain barrier in multiple sclerosis (S. McQuaid, J. Kirk).
    The blood-brain barrier in diabetes mellitus: A critical review of clinical and experimental findings (E. Tolia et al.).
    Final discussion (A.G. de Boer).
    Novel opportunities for the treatment of brain diseases (A.G. de Boer).
    Author index.
    Keyword index.
Komentarze (0)